spacer
home > epc > summer 2019 > fit for purpose
PUBLICATIONS
European Pharmaceutical Contractor

Fit for Purpose




Clinical trials remain the gold standard for establishing safety and efficacy for medical products, but results generated from a carefully structured protocol do not reflect real-world settings and may not be generalisable to scenarios at home and in the clinic. Physicians, their patients, and payers each have a stake in ensuring that results from clinical studies determine the most complete benefit-risk profile possible; as a result, interest in developing real-world evidence (RWE) is on the rise. Increased attention to regulatory applications of RWE is a response to regulatory authorities issuing guidelines for trial designs that include randomised pragmatic trials, as well as studies that employ non-interventional RWE to test effectiveness and safety (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the authors

 
Marni Hall, Vice President of Clinical Evidence in the Center of Advanced Evidence Generation at IQVIA, leverages her expertise in regulatory science, drug safety, and patient centricity to provide scientific oversight and strategic direction on the expanded use of RWE. Marni has two decades of experience in both science and policy and has been responsible for developing data standards, sourcing, and analysing datasets, overseeing the delivery of commercial research programmes and the execution of an agenda for use of patient-generated health data in clinical and regulatory decision making.

 
 
Nicola Stanislaus PhD, Director of Project Management (Europe) at IQVIA Biotech, is responsible for overseeing study management within IQVIA Biotech’s oncology team. Nicola has more than 15 years’ experience in the conduct and oversight of oncology clinical trials and provides strategic leadership, oversight, training, and ongoing evaluation and support to the clinical operations group.


 
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers
 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement